Congenital Heart Disease in Premature Infants 25-32 Weeks' Gestational Age

Patricia Y Chu1, Jennifer S Li2, Andrzej S Kosinski3

  • 1Duke University School of Medicine, Durham, NC.

The Journal of Pediatrics
|November 7, 2016
PubMed

Insights

Congenital heart defects (CHDs) are more common in premature infants, significantly increasing their mortality risk. Early intervention and efforts to prevent premature birth are crucial for affected infants.

Area of Science:

  • Neonatalogy
  • Pediatric Cardiology
  • Public Health

Background:

  • Congenital heart defects (CHDs) are a significant concern in neonatal care.
  • Premature infants face unique challenges, and the prevalence and impact of CHDs in this population require detailed investigation.

Purpose of the Study:

  • To determine the birth prevalence of congenital heart defects (CHDs) in very/extremely premature infants.
  • To compare mortality rates between premature infants with and without CHDs.

Main Methods:

  • Utilized the Kids' Inpatient Databases (2003-2012).
  • Estimated birth prevalence of CHDs (excluding PDA) in infants born between 25-32 weeks gestational age.
  • Employed multivariable logistic regression to assess mortality risks.

Main Results:

  • Identified 28,806 CHDs among 249,011 very/extremely premature infants; overall prevalence was 116 per 1000 births.
  • Severe CHDs were significantly more prevalent in premature infants (7.4 per 1000) compared to term infants (1.5 per 1000).
  • Premature infants with severe CHDs had a 26.3% in-hospital mortality and a 7.5-fold increased odds of death; mortality varied by defect type.

Conclusions:

  • Increased prevalence and mortality of severe CHDs in premature infants underscore the need for targeted interventions.
  • Intensive interventions to decrease premature delivery are warranted for pregnancies diagnosed with fetal CHD.
Abstract

Related Concept Videos

Development of the Heart01:27

Development of the Heart

The development of the human heart, a crucial organ, commences from the mesoderm on the 18th or 19th day after fertilization. This process initiates in the cardiogenic area, a group of mesodermal cells at the embryo's head end, which evolves into elongated strands known as cardiogenic cords. These cords undergo a transformation to form hollow-centered endocardial tubes.
As the embryo undergoes lateral folding, these paired tubes approach each other, merging into a single primitive heart...
3.3K
Teratogenicity01:07

Teratogenicity

The ability of a drug to produce structural deformations and functional abnormalities in the developing embryo or the fetus is called teratogenicity, and the drug producing this effect is known as a teratogen. Teratogenic effects include stillbirth, miscarriage, intrauterine growth restriction, and neurocognitive delay. A teratogen may affect the embryo at different stages of development, which is important in determining the type and extent of the damage. During blastocyst formation, the early...
4.4K
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
700
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
607
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
504
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.1K